Condition
Hair Loss
Early-stage research in androgenetic alopecia.
Quick summary
- • Measured by trichoscopic hair density
- • Follow-up is often only 3–6 months
Overview
Androgenetic alopecia is common and already has standard treatments.
Mechanisms studied
Perifollicular circulation and growth factors are studied.
Human research
Few studies compare with PRP.
Safety
Reported adverse events are mostly local — swelling, pain, or bruising at the harvest and injection sites. Infection and cell-processing quality remain the key risks to monitor.
Evidence limitations
Existing studies are limited by sample size, methodology, and follow-up, and SVF preparation differs substantially between centres, making cross-study comparison difficult.
Related research
- Level CSystematic Review
Adipose-derived stromal vascular fraction (SVF) for the treatment of androgenic alopecia (AGA): a systematic review
Screened 140 articles and retained nine; all reported a statistically significant increase in hair density with no serious adverse events.
- 2023
- Italy
- Level BSystematic Review
The safety and efficacy of autologous adipose-derived stromal vascular fraction for nonscarring alopecia: A systematic review
Six studies with 188 patients, including three RCTs; all found improved hair density with no reported severe adverse events.
- 2022
- United States
- n = 188
Last updated: 2026-06-18 · arisa-w